{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:24:33Z","timestamp":1793467473889,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UH3CA239105"],"award-info":[{"award-number":["UH3CA239105"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Circulating tumor DNA (ctDNA) \u2018tumor fraction\u2019 (TF) may correlate with therapy response, but little is known regarding TF dynamics immediately after therapy initiation. Plasma samples from a single-arm clinical trial enrolling patients with triple-negative breast cancer were collected at a variety of time points following infusion of onalespib (day -7), paclitaxel (day 1), and onalespib + paclitaxel (day 8). 313 samples from 14 patients underwent shallow whole genome sequencing and TF determination. The primary objective was to evaluate TF change from pre-infusion to 6\u2009h and 24\u2009h post-infusion. There was significant TF decline from pre-infusion to 6\u2009h for paclitaxel (p\u2009=\u20090.03) but no change for onalespib or onalespib+paclitaxel at 6hl. There was no ctDNA TF surge within minutes to 24\u2009h of onalespib, paclitaxel, or combination, despite an overall decline in TF during the first therapy cycle. However, there was significant decline in TF from pre-infusion to D9 (16% to 6.5%, p\u2009=\u20090.004). These findings support further research on ctDNA dynamics immediately after therapy initiation.<\/jats:p>","DOI":"10.1038\/s41523-026-00953-w","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:42:06Z","timestamp":1776332526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute circulating tumor DNA dynamics during and after systemic therapy initiation for advanced triple-negative breast cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Briana","family":"To","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Prasath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deloris","family":"Veney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Adalsteinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3388-7069","authenticated-orcid":false,"given":"Dionisia","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"953_CR1","doi-asserted-by":"crossref","unstructured":"Stover, D. G. et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. (2018).","DOI":"10.1200\/JCO.2017.76.0033"},{"key":"953_CR2","unstructured":"Rossi, G. et al. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. (2018)."},{"key":"953_CR3","doi-asserted-by":"crossref","unstructured":"Reichert, Z. R. et al. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann. Oncol. (2023).","DOI":"10.1016\/j.annonc.2022.09.163"},{"key":"953_CR4","unstructured":"Goldberg, S. B. et al. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. (2018)."},{"key":"953_CR5","unstructured":"Cheng, M. L. et al. Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. JCO Precis. Oncol. PO.20.00419 (2021)."},{"key":"953_CR6","doi-asserted-by":"crossref","unstructured":"Hrebien, S. et al. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. (2019).","DOI":"10.1093\/annonc\/mdz085"},{"key":"953_CR7","doi-asserted-by":"crossref","unstructured":"Gouda, M. A. et al. Longitudinal monitoring of circulating tumor DNA to predict treatment outcomes in advanced cancers. JCO Precis. Oncol. (2022).","DOI":"10.1200\/PO.21.00512"},{"key":"953_CR8","doi-asserted-by":"crossref","unstructured":"O\u2019Leary, B. et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat. Commun. (2018).","DOI":"10.1038\/s41467-018-03215-x"},{"key":"953_CR9","doi-asserted-by":"crossref","unstructured":"Pascual, J. et al. Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive\/HER2-negative metastatic breast cancer patients. Clin. Cancer Res. (2023).","DOI":"10.1158\/1078-0432.24304752.v1"},{"key":"953_CR10","doi-asserted-by":"crossref","unstructured":"Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. (2008).","DOI":"10.1038\/nm.1789"},{"key":"953_CR11","unstructured":"Lo, Y. M. et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res. (2000)."},{"key":"953_CR12","unstructured":"Lazare, S. et al. Postoperative lymph is a proximal source of ctDNA for detection of recurrence in HPV-independent head and neck cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. (2026)."},{"key":"953_CR13","doi-asserted-by":"publisher","unstructured":"Neuberger, E. W. I. et al. Assessing the exercise-related kinetics of circulating cell-free DNA, circulating tumour DNA, DNase I activity and cytokines in patients with solid tumours: A pilot study. Exp. Physiol. https:\/\/doi.org\/10.1113\/EP092167 (2025).","DOI":"10.1113\/EP092167"},{"key":"953_CR14","doi-asserted-by":"crossref","unstructured":"Sanz-Garcia, E., Zhao, E., Bratman, S. V. & Siu, L. L. Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges. Sci. Adv. 8 (2022).","DOI":"10.1126\/sciadv.abi8618"},{"key":"953_CR15","doi-asserted-by":"crossref","unstructured":"Williams, N. O. et al. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer. Ther. Adv. Med. Oncol. (2023).","DOI":"10.1177\/17588359231217976"},{"key":"953_CR16","doi-asserted-by":"crossref","unstructured":"Jakobsen, A. K. M. & Spindler, K.-L. G. ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology. Eur. J. Cancer Oxf. Engl. 1990 (2023).","DOI":"10.1016\/j.ejca.2022.11.039"},{"key":"953_CR17","doi-asserted-by":"crossref","unstructured":"Turner, N. et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. Lond. Engl. (2023).","DOI":"10.2217\/fon-2022-1196"},{"key":"953_CR18","unstructured":"Bidard, F.-C. et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. (2022)."},{"key":"953_CR19","doi-asserted-by":"crossref","unstructured":"Bidard, F.-C. et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N. Engl. J. Med. (2025).","DOI":"10.1056\/NEJMoa2502929"},{"key":"953_CR20","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Herrero, E. et al. Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis. Front. Oncol. 12, (2022).","DOI":"10.3389\/fonc.2022.943253"},{"key":"953_CR21","unstructured":"Janke, F. et al. Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re-radiotherapy. Int. J. Cancer (2025)."},{"key":"953_CR22","doi-asserted-by":"crossref","unstructured":"Rickles-Young, M. et al. Assay Validation of Cell-Free DNA Shallow Whole-Genome Sequencing to Determine Tumor Fraction in Advanced Cancers. J. Mol. Diagn. JMD (2024).","DOI":"10.1016\/j.jmoldx.2024.01.014"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00953-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00953-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00953-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:28:05Z","timestamp":1781220485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00953-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["953"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00953-w","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Christian Rolfo\n                      : Advisory Board\/Speaker: AstraZeneca, Daiichi Sankyo, Regeneron and Novocure; Bristol-Myers Squibb, Novartis, Guardant Health, COR2ED, Bayer, Boehringer Ingelheim, AbbVie, Invitae, Janssen, EMD Serono, OneCell Dx, Neogenomics, Touch Oncology, Pfizer. Research Grants: Astra Zeneca, Thermo Fisher, Oncohost, Lung Cancer Research Foundation, National Foundation for Cancer Research, and U54 (National Institute of Health), Research collaborations: GuardantHealth, Foundation Medicine, Roche Diagnostics, EMD Serono, Janssen Pharmaceutical (LUNGMAP S1900J trial). Scientific advisory board member of Imagene AI.\n                      Daniel Stover:\n                      Advisory Board Natera, Guardant. Research funding (in kind to institution): NeoGenomics, Foundation Medicine.\n                      Viktor Adalsteinsson:\n                      royalties paid and research funding from Exact Sciences; co-founder and advisor of Amplifyer Bio. All other authors in this manuscript declare no competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}